Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + Gemcitabine vs OFF for Gemcitabine-Refractory Pancreatic Cancer
NCT02506842Phase 3Unknown
- Sponsor
- Fudan University
- Start
- Jun 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Fudan University. Status: unknown.
02
Drugs
paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02506842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02506842.